

Florida Medical Association
American Academy of Allergy, Asthma and Immunology,
Fellow of AAAAI
Vice-Chairman Ozone Depleting Substances Committee
Florida Allergy and Immunology Society (FAIS) 1978;
Secretary-Treasurer FAIS
President Elect FAIS
President FAIS
American College of Physicians, Fellow

American College of Allergy & Immunology (ACAI) Fellow
Chairman of Therapeutics Committee
Chairman Membership Recruitment Committee
Secretary
Chairman Scientific Council
Chairman By-Laws Comm.
Vice-President
President Elect
President American College of Allergy, Asthma & Immunology
ACAAI representative to the Stakeholders Group
Chairman Immunotherapy Committee
Chairman Nominations Committee
Chairman Immunotherapy Committee
Budget Committee, International Committee

Joint Council of Allergy, Asthma and Immunology,
Board of Directors

New York Allergy Society NYAS
NYAS Board of Directors
NYAS Public Relations Chair

American Association of Certified Allergists: Board of Directors
Secretary-Elect
Secretary
Vice President
President Elect
President
Board of Directors

FDA Allergenic Advisory Committee: 3 year appointment beginning 2015

8) Academic appointments:

**Clinical Instructor, Medicine; University of Miami
School of Medicine
Clinical Assistant Professor Medicine; University of
Miami School of Medicine
Clinical Associate Professor; Medicine; University of
Miami School of Medicine
Clinical Professor; Medicine; University of Miami
School of Medicine
Clinical Associate Professor Pediatrics, University of
Miami School of Medicine
Assistant Clinical Professor Columbia University
Department of Medicine:
Clinical Professor of Medicine; Columbia University
Department of Medicine:
Professor of Medicine; Icahn School of Medicine at
Mount Sinai**

9) Hospital appointments:

**Attending Physician;
Memorial Hospital, Hollywood, Florida
Attending Physician;
Hollywood Medical Center Hollywood, Florida**

**Assistant Attending Physician; Beth Israel Medical
Center, New York,
Attending Physician; Beth Israel Medical Center, New
York**

**Senior Attending Physician St. Luke's Roosevelt
Hospital Center
Assistant Chief of Allergy and Infectious Disease
Section, Department of Medicine, St. Luke's-Roosevelt
Medical Center, Now Mount Sinai West
Director of Outpatient Allergy Clinic St. Luke's
Roosevelt Hospital Center
Chief of Division of Allergy and Clinical Immunology,
Department of Medicine**

**Attending Physician Montefiore Sound Shore Med Ctr.,
New Rochelle NY**

White Plains Medical Center Consultant in Allergy

**Consulting Physician in Allergy, Lawrence Hospital,
Bronxville, New York**

10) Honors:

**Phi Beta Kappa
Magna Cum Laude
Honors in Chemistry
Jonas Salk Scholarship
Univ. of Chicago Scholarship
Summer Fellowship Path. Dept.
Mount Sinai Hosp., N.Y.
Alpha Omega Alpha
Mead-Johnson SAMA Honorable Mention
Sheard-Sandford Award
M.D. with Honors
Amer Soc Path. Award
Distinguished Fellow American College of Allergy,
Asthma and Immunology
Miembro Honorario de la Sociedad Dominica de
Alergia e Immunologia Clinica
Distinguished Service Award, American College of
Allergy, Asthma and Immunology
Gold Cane award from American College of Allergy,
Asthma and Immunology for Lifetime Achievement in
Allergy**

11) Fellowships and grants: NA

12) Departmental and University Committees:

**Executive Committee of Department of Medicine
Mount Sinai St. Luke's-Roosevelt Hospital**

13) Teaching experience and responsibilities:

**Attending Physician
Jackson Memorial Hospital, University of Miami School
of Medicine, Rounds in Internal Medicine
Preceptor for physical diagnosis and history taking
course at University of Miami
Attending Physician at the Pediatric Outpatient Allergy
Clinic Director of this weekly Clinic
Columbia University School of Medicine Elective in
Clinical Allergy for 4th year students)
St Luke's- Roosevelt Hosp. Ctr, Elective for house staff:
Lecture: Sophie Davis School of Medicine
Grand Rounds: LICH Allergy, Lawrence Hospital.
Featured speaker Annual Meetings of American College**

**of Allergy, Asthma and Immunology American
Academy of Allergy, Asthma and Immunology,
European Academy Allergy and Clinical Immunology**

14) Other:

15) Publications

A. Original peer reviewed articles:

- 1. Fahey JL, Finegold I, Rabson AS, and Manaker RA. Immunoglobulin synthesis in vitro by established human cell lines. Science; 1966;152; 1259-1261.**
- 2. *Finegold I, Fahey JL, and Granger H. Synthesis of immunoglobulins by human cell lines in tissue culture. J. Immunology; 1967; 99; 839-848.**
- 3. *Finegold I, Fahey JL, and Hirshaut Y. Immunochemical and morphologic comparison of donor tissues with immunoglobulin producing tissue culture lines from two patients. Cancer Research; 1968; 23; 1538, 1968.**
- 4. *Finegold I, Fahey JL, and Dutcher TF. Immunofluorescent studies of immunoglobulins in human lymphoid cells in continuous culture. J. Immunology; 1968; 101; 366-373.**
- 5. Fahey JL and Finegold I. Synthesis of immunoglobulins in human lymphoid cell lines, Cold Spring Harbor Symp. on Quantitative Biology; 1968; 32; 283-289.**
- 6. Sanders JH, Fahey JL, Finegold I, Ein D, Reisfeld R. and Berard C. Multiple anomalous immunoglobulins. American J. Medicine; 1969; 47; 43-59.**
- 7. *Finegold I, and Middleton E. Positive Lupus Erythematosus preparations and penicillin sensitivity. J. Allergy; 1971; 48; 115-119.**
- 8. *Finegold I. A two-year pollen and mold spore survey of southeast Florida. Annals of Allergy; 1975; 35: 37-41.**
- 9. *Finegold I. Allergic reactions to molds. Cutis; 1976; 17: 1080-1085.**
- 10. *Finegold I. Allergy and Tourette's Syndrome. Annals of Allergy; 1985; 55: 119-121.**
- 11. *Finegold, I. Allergy to Silicone: Is it Real? Compr. Therapy; 1996; 22: 393-398.**
- 12. *Finegold I. What's in a name? Vaccine versus extracts. Editorial in Annals of Allergy; 1998; 81: 377.**
- 13. Ross RN, Nelson HS, Finegold I. Effectiveness of specific immunotherapy in the treatment of asthma: A meta-analysis of prospective, randomized, double-blind, placebo-**

controlled studies. *Clinical Therapeutics*; 2000; 22:329-341.

14. Ross RN, Nelson HS, Finegold I. Effectiveness of specific immunotherapy in the treatment of allergic rhinitis: A meta-analysis of prospective, randomized, double-blind, placebo-controlled studies. *Clinical Therapeutics* 22; 2000;342-350.

15. Ross RN, Nelson HS, Finegold I. Effectiveness of specific immunotherapy in the treatment of Hymenoptera venom sensitivity: A meta-analysis. *Clinical Therapeutics*; 2000;22:351-358.

16. Butrus S, Greiner JV, Discepola M and Finegold, I. Comparison of the clinical efficacy and comfort of olopatadine hydrochloride 0.1% ophthalmic solution and nedocromil sodium 2% ophthalmic solution in the human conjunctival allergen challenge model. *Clinical Therapeutics*;2000; 22:1462-1472.

17. *Finegold I. Analyzing meta-analyses of specific immunotherapy in the treatment of asthma. *Annals of Allergy*; 2001; 87: S33-37.

18. *Finegold I, Lanier RQ, Berger W, Blaiss M. Immunotherapy for asthma. *Am J Respir Crit Care Med*. 2002 May 15;165(10):1453-4.

19.*Finegold I.Is immunotherapy effective in allergic disease? *Curr Opin Allergy Clin Immunol*. 2002 Dec;2(6):537-40.

20.*Finegold I.A significant evolutionary step in the specialty of allergy and immunology. *Ann Allergy Asthma Immunol*. 2003 Jan;90(1):13-4.

21.*Finegold I.Immunotherapy and asthma. *J Asthma*. 2003;40 Suppl:31-5.PMID

22.*Finegold I. Immunotherapy in the age of anti-IgE.*Clin Rev Allergy Immunol*. 2004 Oct;27(2):75-82.

23. Lanier BQ, Finegold I, D'Arenzio P, Granet D, Epstein AB, Ledgerwood GL. Clinical Efficacy of olopatadine vs epinastine ophthalmic solution in the conjunctival allergen challenge model. *Current Medical Research and Opinions*; 2005; 20:1227-1233.

24. Cox LS, Linnemann DL, Nolte H, Weldon D, Finegold I, Nelson HS. Sublingual immunotherapy: a comprehensive review. *J Allergy Clin Immunol*; 2006; 117:1021-35.

25. Finegold, I; Granet, D; D'Arenzio, P; Epstein, A; Efficacy and response with olopatadine versus epinastine in ocular allergic symptoms: a post hoc analysis of data from a conjunctival allergen challenge study. *Clinical Therapeutics*; 2006;28:1630-1638.

26.*Finegold, I Enhancing efficacy, safety, and convenience of immunotherapy: a workshop presentation. *Ann Allergy Asthma Immunol*. 2006 Feb;96(2 Suppl 1):S26-30

27.*Finegold, I; Allergen Immunotherapy: Present and future. Allergy Asthma Proc 28:44-49, 2007.

28.*Finegold, I. Immunotherapy: When to initiate treatment in children. Allergy Asthma Proc 28:698-705, 2007.

29. Cox L, Platts-Mills T, Finegold I, Schwartz LB, Simons ER, Wallace DV. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on Omalizumab-associated anaphylaxis. J Allergy Clin Immunol 120:1373-7, 2007.

30*.Finegold, I Nontuberculous mycobacterial infection in the differential diagnosis of chronic cough. Allergy Asthma Proc. 2008 May-Jun;29(3):343-4

31*Finegold, I Issues in stinging insect allergy immunotherapy: a review. Curr Opin Allergy Clin Immunol. 2008 Aug;8(4):343-7. Review

32.* Finegold I, Immunotherapy at the ACAAI Annual Meeting. Immunotherapy. 2009 Mar;1(2):177-9.

34. *Finegold I, Dockhorn RJ, Ein D, Dolen WK, Oppenheimer J, Potter LH. Immunotherapy throughout the decades: from Noon to now. Ann Allergy Asthma Immunol. 2010 Nov;105(5):328-36; quiz 337, 358.

35.*Finegold I, Oppenheimer J. Immunotherapy . The next one hundred years. Ann Allergy Asthma Immunol. 2010 Nov;105(5):394-8.

36. Pajno GB and Finegold I. SIT beyond respiratory diseases. Ann Allergy Asthma Immunol. 2011 Nov;107(5):395-400.

37. Bernstein DI, Blaiss MS, Cox LS, Finegold I, Lanier RQ, Nelson HS, Wallace D. Current standards and future directions in immunotherapy: perspectives on challenges and opportunities for the allergist. Ann Allergy Asthma Immunol. 2011 Nov;107(5): 422-425.

38. Larenas-Linnemann DE, Finegold I, Nelson H. Food and Drug Administration reclassification of allergens for diagnosis and treatment: now is the time to be heard. Ann. Allergy Asthma Immunol. 2012;109:6-9.

B. Case Reports:

1. *Finegold I. Oral desensitization to trimethoprim-sulfamethoxazole in a patient with acquired immunodeficiency syndrome. J. Allergy and Clin Immunol; 1986; 78: 905-908.

2. Kukar A, Chawla R, Finegold I. Acquired angioedema. Resident and Staff Physician; 2005; 151:35-43.

C. Reviews, Chapters and Editorials:

1. *Finegold I. Manpower, quality care, ethics and survival for allergists. Annals of Allergy, Asthma & Immunology; 1995; 74: 229-233.

2. *Finegold I. Chapter 6. Adverse reactions to food additives. In Food Hypersensitivity and Adverse Reactions. Ed: Frieri M. and Kettelhut B. Marcel Dekker, New York. 1999. p.113-124.

3. *Finegold I. Immunotherapy historical perspective. Annals of Allergy; 2001; 87:S3-4.

4. *Finegold I. Editor: Proceedings of the Immunotherapy in Allergic Asthma Consensus Conference August 19-20, 2000. Annals of Allergy; 2001; 87: S1-69.

5. *Finegold I. Is immunotherapy effective in allergic disease? Current Opinion Allergy Clin Immunol; 2002; 2:537-540.

6. *Finegold, I. Using allergen immunotherapy: A shot in the arm for allergy control. J Respir Dis; 2003; 24:21-26.

7. *Finegold, I. A significant evolutionary step in the specialty of allergy and immunology. Annals of Allergy; 2003; 90: 13-14.

8. *Finegold, I. Immunotherapy and Asthma. Journal of Asthma; 2003; 40:Suppl. 31-35.

9. *Finegold, I. The Allergic Eye. Alergia Astma Immunologia. Krakow Conference Poland, July 31-August 3, 2004; 9:Suppl.3. 38-41.

10. *Finegold, I. Immunotherapy in the Age of Anti-IgE. Clinical Reviews in Allergy and Immunology; 2004; 27:75-82.

11. *Finegold I. Chapter 22. Immunotherapy: Vaccines for allergic diseases. In Atlas of Allergies and Clinical Immunology. Ed: Philip Fireman. Mosby, Pa. 2005. p. 369-378.

D. Patents:

NA

E. Abstracts:

1. Finegold I, Wissler R, and Dzoga K. Transplant immunity and immunological enhancement. Proc Amer Assoc Cancer Research; 1964; 5:18.

- 2. Finegold I. Silicone breast implant disorders. Annals of Allergy; 1994; 72: 56,1994.**
- 3. Finegold I, Miles R, Leahigh A. Erangey M, Mugalian R. Allergy public awareness: results of a national opinion survey. Annals of Allergy; 2000; 84:123.**
- 4. Finegold I. Reducing rush immunotherapy systemic reactions with a modification of radiocontrast media prophylaxis. Annals of Allergy; 2005; 94:110.**

F. Audiovisual/Media

Finegold, I. Immunotherapy. Current Views in Allergy and Immunology. Volume 33; 2005., January 2009: Update Sublingual immunotherapy

G. Media trained. Spokesman for allergy in all media.

H. National and International speaker at numerous meetings and courses.

I. Listed in a number of referral bases for Allergy , Immunology, Non Tuberculous Mycobacterial disease.